Illinois General Assembly - Full Text of HB1034
Illinois General Assembly

  Bills & Resolutions  
  Compiled Statutes  
  Public Acts  
  Legislative Reports  
  IL Constitution  
  Legislative Guide  
  Legislative Glossary  

 Search By Number
 (example: HB0001)
Search Tips

Search By Keyword

Full Text of HB1034  103rd General Assembly

HB1034 103RD GENERAL ASSEMBLY

  
  

 


 
103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024
HB1034

 

Introduced 1/12/2023, by Rep. Mary E. Flowers

 

SYNOPSIS AS INTRODUCED:
 
410 ILCS 620/16.2 new

    Amends the Illinois Food, Drug and Cosmetic Act. Provides that the amendatory provisions apply to any manufacturer of a prescription drug that is purchased or reimbursed by specified parties. Provides that a manufacturer of a prescription drug with a wholesale acquisition cost of more than $40 for a course of therapy shall notify specified parties if the increase in the wholesale acquisition cost of the prescription drug is more than 10%, including the proposed increase and cumulative increase. Provides that the notice of price increase shall be provided in writing at least 60 days prior to the planned date of the increase. Provides that no later than 30 days after notification of a price increase or new prescription drug the manufacturer shall report specified additional information to specified parties. Provides that a manufacturer of a prescription drug shall provide written notice if the manufacturer is introducing a new prescription drug to market at a wholesale acquisition cost that exceeds a specified threshold. Provides that failure to provide notice under the amendatory provisions shall result in a civil penalty of $10,000 per day for every day after the notification period that the manufacturer fails to report the information. Requires the Department of Public Health to conduct an annual public hearing on the aggregate trends in prescription drug pricing. Requires the Department to publish on its website a report detailing findings from the public hearing and a summary of details from reports provided under the amendatory provisions, except for information identified as a trade secret or exempted under the Freedom of Information Act. Provides that the amendatory provisions shall not restrict the legal ability of a pharmaceutical manufacturer to change prices as permitted under federal law.


LRB103 04886 CPF 49896 b

 

 

A BILL FOR

 

HB1034LRB103 04886 CPF 49896 b

1    AN ACT concerning health.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Illinois Food, Drug and Cosmetic Act is
5amended by adding Section 16.2 as follows:
 
6    (410 ILCS 620/16.2 new)
7    Sec. 16.2. Prescription drug price increases.
8    (a) This Section shall apply to any manufacturer of a
9prescription drug that is purchased or reimbursed by any of
10the following:
11        (1) A State purchaser, including, but not limited to,
12    State retirement systems, the Department of Corrections,
13    the Department of Healthcare and Family Services, the
14    Department of Public Health, or any entity acting on
15    behalf of a State purchaser.
16        (2) A health insurer.
17        (3) A health care service plan provider.
18        (4) A pharmacy benefit manager.
19    (b) A manufacturer of a prescription drug with a wholesale
20acquisition cost of more than $40 for a course of therapy shall
21notify each party described in subsection (a) if there is an
22increase in the wholesale acquisition cost of the prescription
23drug of more than 10%, including the proposed increase and

 

 

HB1034- 2 -LRB103 04886 CPF 49896 b

1cumulative increase that has occurred within the previous 2
2calendar years prior to the date of the proposed increase.
3    For purposes of this subsection, "course of therapy" means
4either of the following:
5        (1) The recommended daily dosage units of a
6    prescription drug pursuant to its prescribing label as
7    approved by the federal Food and Drug Administration for a
8    normal course of treatment that is 30 days or more.
9        (2) The recommended daily dosage units of a
10    prescription drug pursuant to its prescribing label as
11    approved by the federal Food and Drug Administration for a
12    normal course of treatment that is less than 30 days.
13    (c) The notice required under subsection (b) shall be
14provided in writing at least 60 days prior to the planned date
15of the increase in the wholesale acquisition cost.
16    (d) No later than 30 days after providing notification of
17a price increase under subsection (b), a manufacturer shall
18report the following information to each party described in
19subsection (a):
20        (1) The latest applicable wholesale acquisition cost.
21        (2) The date of the latest previous increase in
22    wholesale acquisition cost.
23        (3) The per-unit dollar amount of the scheduled
24    increase in wholesale acquisition cost.
25        (4) A schedule of wholesale acquisition cost increases
26    for the previous 5 years, where available, or for the

 

 

HB1034- 3 -LRB103 04886 CPF 49896 b

1    years since the drug has been approved by the federal Food
2    and Drug Administration if that length of time is less
3    than 5 years.
4        (5) The date and price of acquisition, if the drug was
5    not developed by the manufacturer.
6        (6) A description of each financial and nonfinancial
7    factor that contributes to the wholesale acquisition cost,
8    including the following:
9            (A) A percentage of the price attributable to each
10        factor.
11            (B) An explanation of the role of each factor in
12        the price of the drug.
13    (e) A manufacturer of a prescription drug shall provide
14written notice to each party described in subsection (a) if
15the manufacturer is introducing a new prescription drug to
16market at a wholesale acquisition cost that exceeds the
17threshold set for a specialty drug under the Medicare Part D
18program. This notice shall be provided no later than 30 days
19prior to the release of the drug on the commercial market.
20    (f) No later than 30 days after providing the notification
21of a new prescription drug under subsection (e), a
22manufacturer shall report the following information to each
23party described in subsection (a):
24        (1) The latest applicable wholesale acquisition cost.
25        (2) The date of the latest previous increase in
26    wholesale acquisition cost.

 

 

HB1034- 4 -LRB103 04886 CPF 49896 b

1        (3) The per-unit dollar amount of the scheduled
2    increase in wholesale acquisition cost.
3        (4) A schedule of wholesale acquisition costs
4    increases for the previous 5 years, where available, or
5    for the years since the drug has been approved by the
6    federal Food and Drug Administration if that length of
7    time is less than 5 years.
8        (5) The date and price of acquisition, if the drug was
9    not developed by the manufacturer.
10        (6) A description of each financial and nonfinancial
11    factor that contributes to the wholesale acquisition cost,
12    including the following:
13            (A) A percentage of the price attributable to each
14        factor.
15            (B) An explanation of the role of each factor in
16        the price of the drug.
17    (g) Failure to provide the information required under
18subsections (b), (d), (e), or (f) to each party described in
19subsection (a) shall result in a civil penalty of $10,000 per
20day for every day after the notification period that the
21manufacturer fails to provide the information.
22    (h) The Department of Public Health shall conduct an
23annual public hearing on the aggregate trends in prescription
24drug pricing. The hearing shall provide for public discussion
25of overall price increases, emerging trends, decreases in drug
26spending, and the impact of prescription drug spending on

 

 

HB1034- 5 -LRB103 04886 CPF 49896 b

1health care affordability and premiums.
2    (i) The Department of Public Health shall publish on its
3website a report detailing findings from the public hearing
4held under subsection (h) and a summary of information
5provided under subsections (b), (d), (e), and (f).
6    (j) The Department of Public Health may not post on its
7website any information described in subsections (d) or (f) of
8this Section that is identified as a trade secret under the
9Illinois Trade Secrets Act.
10    (k) The Department of Public Health shall keep
11confidential all information provided to the Department that
12would qualify for an exemption under Section 7 of the Freedom
13of Information Act.
14    (l) This Section shall not restrict the legal ability of a
15pharmaceutical manufacturer to change prices as permitted
16under federal law.